Hematology and Immunology Strategic Portfolio Supports Sobi's Narrow Moat
Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...
Experts rubbish 'dangerous' posts touting bitter melon as treatment for rabies
Bitter melon leaves are not a proven treatment for rabies, experts told AFP, refuting "dangerous" online posts touting the ...
hdfncompanion2d
More research needed on preventing HDFN in anti-G pregnancies
A recent study showed limited data exist on the risks associated with anti-G during pregnancy, including the development of ...
Medscape2d
ACP Issues Primary Care Guidance for Episodic Migraine Headache Prophylaxis
The Clinical Guidelines Committee of the American College of Physicians (ACP) has released a new clinical guideline on the ...
TMCnet3d
Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
Orchard Therapeutics, a Kyowa Kirin company, today announced presentations from seven abstracts from across its hematopoietic stem cell (HSC) gene therapy portfolio will be featured at the 21st Annual ...
The American Journal of Managed Care5d
New AGA Guidelines Recommend Risk-Based Prophylaxis for Hepatitis B Reactivation Monitoring
The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...